文献速递认知障碍与痴呆

神经颗粒素与BACE1和主观认知下降个体临床认知衰退的关联

Association of Neurogranin and BACE1 With Clinical Cognitive Decline in Individuals With Subjective Cognitive Decline.
PubMed 文献 · Neurology · 2024-09-20

基于DELCODE队列530名参与者,研究脑脊液神经颗粒素和BACE1与主观认知下降(SCD)者认知衰退的关联。结果显示,神经颗粒素及神经颗粒素/BACE1比值较高者认知下降更快,且转化为轻度认知障碍的风险增加;神经颗粒素对认知衰退的加速作用在SCD组比认知正常对照组更明显。

要点

  • 在SCD个体中,脑脊液神经颗粒素及神经颗粒素/BACE1比值较高与认知下降速度更快相关。
  • 基线神经颗粒素及神经颗粒素/BACE1比值较高与SCD转化为轻度认知障碍的风险增加相关。
  • 神经颗粒素对认知衰退的加速作用在SCD组比认知正常对照组更明显。

核心结论

  • 研究提示脑脊液神经颗粒素和BACE1在阿尔茨海默病临床前期即开始变化,且与SCD个体的临床进展相关。

研究设计与样本

  • 研究纳入DELCODE(德国)队列中有脑脊液神经颗粒素和BACE1测量值的参与者,共分析530人(平均年龄70.76±6.01岁,48.7%为女性)。

主要发现

  • 在SCD个体中,神经颗粒素较高者认知下降更快(β=-0.138,SE=0.065,p=0.037),神经颗粒素/BACE1比值较高者认知下降更快(β=-0.293,SE=0.115,p=0.013)。
  • 基线神经颗粒素较高与SCD向MCI转化率增加相关(每SD的HR 1.35,95%CI 1.03-1.77,p=0.028)。
  • 基线神经颗粒素/BACE1比值较高与SCD向MCI转化率增加相关(每SD的HR 1.53,95%CI 1.13-2.07,p=0.007)。
  • 神经颗粒素较高对认知衰退的加速作用在SCD组比认知正常对照组更明显(β=-0.077,SE=0.033,p=0.020)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: CSF biomarkers have immense diagnostic and prognostic potential for Alzheimer disease (AD). However, AD is still diagnosed relatively late in the disease process, sometimes even years after the initial manifestation of cognitive symptoms. Thus, further identification of biomarkers is required to detect related pathology in the preclinical stage and predict cognitive decline. Our study aimed to assess the association of neurogranin and β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) with cognitive decline in individuals with subjective cognitive decline (SCD). METHODS: We enrolled participants with available neurogranin and BACE1 measurements in CSF from the DELCODE (DZNE-Longitudinal Cognitive Impairment and Dementia, Germany) cohort. The longitudinal change of Preclinical Alzheimer's Cognitive Composite score was assessed as the primary outcome in participants with SCD and controls. The secondary outcome was defined as conversion of SCD to mild cognitive impairment (MCI) during follow-up. Levels of neurogranin, BACE1, and neurogranin/BACE1 ratio across groups were compared by analysis of covariance after adjustment for demographics. The linear mixed-effects model and Cox regression analysis were applied to evaluate their association with cognitive decline and progression of SCD to MCI, respectively. RESULTS: A total of 530 participants (mean age: 70.76 ± 6.01 years, 48.7% female) were analyzed in the study. The rate of cognitive decline was faster in individuals with SCD with higher neurogranin and neurogranin/BACE1 ratio (β = -0.138, SE = 0.065, p = 0.037, and β = -0.293, SE = 0.115, p = 0.013). Higher baseline neurogranin and neurogranin/BACE1 ratio were associated with an increased rate of conversion from SCD to MCI (hazard ratio [HR] 1.35 per SD, 95% CI 1.03-1.77, p = 0.028, and HR 1.53 per SD, 95% CI 1.13-2.07, p = 0.007). In addition, the impact of higher neurogranin levels on accelerating the rate of cognitive decline was more pronounced in the SCD group than in cognitively unimpaired controls (β = -0.077, SE = 0.033, p = 0.020). DISCUSSION: Our findings suggest that CSF neurogranin and BACE1 begin to change in the preclinical stage of AD and they are associated with clinical progression in individuals with SCD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Wang X, Freiesleben SD, Schneider LS, et al. Association of Neurogranin and BACE1 With Clinical Cognitive Decline in Individuals With Subjective Cognitive Decline. Neurology. 2024. PMID: 39303184. doi:10.1212/WNL.0000000000209806

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。